Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Affiliations

¹ Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy. arturo.ciccullo@gmail.com.
² Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
³ Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy.

Comment

Arturo Ciccullo et al. Infection. 2020 Apr.

. 2020 Apr;48(2):309-310.

doi: 10.1007/s15010-019-01379-2. Epub 2019 Nov 29.

¹ Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy. arturo.ciccullo@gmail.com.
² Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
³ Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy.

No abstract available

Comment on

Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L, Vossen MG, Winkler S, Thalhammer F. Tobudic S, et al. Infection. 2019 Dec;47(6):1013-1020. doi: 10.1007/s15010-019-01354-x. Epub 2019 Sep 13. Infection. 2019. PMID: 31520397

1. Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection 2019;47:1013–20. https://doi.org/10.1007/s15010-019-01354-x . - DOI - PubMed
1. Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8:171–84. - DOI
1. Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571–7. https://doi.org/10.1016/j.ijantimicag.2017.11.008 . - DOI - PubMed
1. Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2018;6:ofy331. https://doi.org/10.1093/ofid/ofy331 . - DOI - PubMed - PMC
1. Knafl D, Tobudic S, Cheng SC, et al. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36:677–80. https://doi.org/10.1007/s10096-016-2845-z . - DOI - PubMed